{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:06:25Z","timestamp":1759989985889,"version":"3.44.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"am","delay-in-days":261,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA014520","T32CA090217"],"award-info":[{"award-number":["P30CA014520","T32CA090217"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jss.2022.09.025","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T07:47:38Z","timestamp":1666252058000},"page":"137-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K\/mTOR Inhibitors"],"prefix":"10.1016","volume":"282","author":[{"given":"Laura C.","family":"Gunder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyra H.","family":"Moyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-5143","authenticated-orcid":false,"given":"Hillary R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S.","family":"Auyeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen E.","family":"Leverson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina A.","family":"Matkowskyj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evie H.","family":"Carchman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2022.09.025_bib1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jnci\/djz219","article-title":"Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001-2015","volume":"112","author":"Deshmukh","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jss.2022.09.025_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cncr.20364","article-title":"Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000","volume":"101","author":"Johnson","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jss.2022.09.025_bib3","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jss.2022.09.025_bib4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2147\/OTT.S38217","article-title":"Current treatment options for management of anal intraepithelial neoplasia","volume":"6","author":"Weis","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jss.2022.09.025_bib5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1053\/j.scrs.2017.04.006","article-title":"Topical therapies for the treatment of anal high-grade squamous intraepithelial lesions","volume":"28","author":"Megill","year":"2017","journal-title":"Semin Colon Rectal Surg"},{"key":"10.1016\/j.jss.2022.09.025_bib6","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.cell.2013.11.019","article-title":"Autophagy-mediated tumor promotion","volume":"155","author":"Guo","year":"2013","journal-title":"Cell"},{"issue":"Suppl 2","key":"10.1016\/j.jss.2022.09.025_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00105-020-04562-x","article-title":"Anal dysplasia and anal cancer. English version","volume":"71","author":"Wieland","year":"2020","journal-title":"Hautarzt"},{"key":"10.1016\/j.jss.2022.09.025_bib8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.virol.2011.09.018","article-title":"Dominant role of HPV16 E7 in anal carcinogenesis","volume":"421","author":"Thomas","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.jss.2022.09.025_bib9","series-title":"Chapter 4 - Neoplasia, Coleman WB, Tsongalis GJ. Essential Concepts in Molecular Pathology","first-page":"55","author":"Coleman","year":"2020"},{"key":"10.1016\/j.jss.2022.09.025_bib10","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1158\/1940-6207.CAPR-10-0086","article-title":"A mouse model for human anal cancer","volume":"3","author":"Stelzer","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.jss.2022.09.025_bib11","doi-asserted-by":"crossref","first-page":"e611","DOI":"10.1016\/S1470-2045(15)00292-2","article-title":"Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention","volume":"16","author":"Bernardi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jss.2022.09.025_bib12","doi-asserted-by":"crossref","first-page":"43594","DOI":"10.18632\/oncotarget.6202","article-title":"Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas","volume":"6","author":"Smaglo","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jss.2022.09.025_bib13","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/bjc.2016.144","article-title":"Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection","volume":"114","author":"Cacheux","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2022.09.025_bib14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.18632\/oncotarget.23066","article-title":"Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma","volume":"9","author":"Cacheux","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jss.2022.09.025_bib15","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/annonc\/mdw152","article-title":"Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes","volume":"27","author":"Chung","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jss.2022.09.025_bib16","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1541-7786.MCR-17-0060","article-title":"Comprehensive genomic profiling of metastatic squamous cell carcinoma of the anal canal","volume":"15","author":"Morris","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.jss.2022.09.025_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jss.2022.09.025_bib18","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1158\/1078-0432.CCR-18-2843","article-title":"Activating mutations in Pik3ca contribute to anal carcinogenesis in the presence or absence of HPV-16 oncogenes","volume":"25","author":"Shin","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2022.09.025_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy","volume":"12","author":"Hua","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jss.2022.09.025_bib20","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.3748\/wjg.v20.i15.4178","article-title":"Targeting mTOR network in colorectal cancer therapy","volume":"20","author":"Wang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jss.2022.09.025_bib21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/CEJ.0000000000000505","article-title":"Topical application of a dual PI3K\/mTOR inhibitor prevents anal carcinogenesis in a human papillomavirus mouse model of anal cancer","volume":"28","author":"Rademacher","year":"2019","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.jss.2022.09.025_bib22","first-page":"1","article-title":"Dysregulation of autophagy contributes to","volume":"11","author":"Carchman","year":"2016","journal-title":"Anal Carcinogenesis PLoS One"},{"key":"10.1016\/j.jss.2022.09.025_bib23","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/sj.bjc.6603180","article-title":"Increased expression of pAKT is associated with radiation resistance in cervical cancer","volume":"94","author":"Kim","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2022.09.025_bib24","doi-asserted-by":"crossref","first-page":"111690","DOI":"10.1016\/j.mrfmmm.2020.111690","article-title":"Targeting AKT\/PKB to improve treatment outcomes for solid tumors","volume":"819-820","author":"Iida","year":"2020","journal-title":"Mutat Res"},{"key":"10.1016\/j.jss.2022.09.025_bib25","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1940-6207.CAPR-10-0228","article-title":"Rapamycin inhibits anal carcinogenesis in two preclinical animal models","volume":"3","author":"Stelzer","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.jss.2022.09.025_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms20030755","article-title":"mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy","volume":"20","author":"Tian","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jss.2022.09.025_bib27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","article-title":"Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis","volume":"18","author":"Lin","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jss.2022.09.025_bib28","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/488S2a","article-title":"HPV: the global burden","volume":"488","author":"Crow","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jss.2022.09.025_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-015-0361-x","article-title":"The role of the PI3K\/Akt\/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses","volume":"14","author":"Zhang","year":"2015","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jss.2022.09.025_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.02323-18","article-title":"Repression of human papillomavirus oncogene expression under hypoxia is mediated by PI3K\/mTORC2\/AKT signaling","volume":"10","author":"Bossler","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.jss.2022.09.025_bib31","doi-asserted-by":"crossref","first-page":"9398","DOI":"10.1128\/JVI.00974-10","article-title":"The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis","volume":"84","author":"Spangle","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.jss.2022.09.025_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.12703\/P7-13","article-title":"The phosphoinositide 3-kinase pathway and therapy resistance in cancer","volume":"7","author":"Brown","year":"2015","journal-title":"F1000prime Rep"},{"key":"10.1016\/j.jss.2022.09.025_bib33","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1128\/JVI.02319-12","article-title":"Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase\/Akt\/mTOR pathway and inhibition of autophagy","volume":"87","author":"Surviladze","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.jss.2022.09.025_bib34","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nature17963","article-title":"Overcoming mtor resistance mutations with a new-generation mtor inhibitor","volume":"534","author":"Rodrik-Outmezguine","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jss.2022.09.025_bib35","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2008.06.014","article-title":"Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110\u03b1","volume":"14","author":"Zunder","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jss.2022.09.025_bib36","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.2174\/0929867321666140414101528","article-title":"Four major factors regulate phosphatidylinositol 3-kinase signaling pathway in cancers induced by infection of human papillomaviruses","volume":"21","author":"Wu","year":"2014","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jss.2022.09.025_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2014.00064","article-title":"Targeting PI3K\/Akt\/mTOR signaling in cancer","volume":"4","author":"Porta","year":"2014","journal-title":"Front Oncol"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480422006072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480422006072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:00:38Z","timestamp":1758380438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022480422006072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":37,"alternative-id":["S0022480422006072"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2022.09.025","relation":{},"ISSN":["0022-4804"],"issn-type":[{"type":"print","value":"0022-4804"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K\/mTOR Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2022.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}